This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aprea Therapeutics’s 8K filing here.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Recommended Stories
- Five stocks we like better than Aprea Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Market Volatility Creates Opportunity in These 3 Value Stocks
- Investing In Automotive Stocks
- Visa and Mastercard Remain Strong Plays as Consumers Keep Swiping
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 2 High-Yield Consumer Staples Stocks Ready to Deliver Big Returns
